Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Atara Biotherapeutics (ATRA – Research Report) and Akebia Therapeutics (AKBA – Research Report).
Atara Biotherapeutics (ATRA)
In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Atara Biotherapeutics, with a price target of $28.00. The company’s shares closed last Tuesday at $2.14, close to its 52-week low of $1.45.
According to TipRanks.com, Burns is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Atara Biotherapeutics with a $20.98 average price target.
See today’s best-performing stocks on TipRanks >>
Akebia Therapeutics (AKBA)
H.C. Wainwright analyst Ed Arce maintained a Hold rating on Akebia Therapeutics today and set a price target of $2.00. The company’s shares closed last Tuesday at $1.23.
According to TipRanks.com, Arce is a 5-star analyst with an average return of
Currently, the analyst consensus on Akebia Therapeutics is a Moderate Buy with an average price target of $2.67.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ATRA:
